MedTrace Logo

Association Between Cerebral Blood Flow Change and Cognitive Function in Hemodialysis Patients

NCT05555836 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 121

Last updated 2022-09-27

No results posted yet for this study

Summary

The prevalence of cognitive impairment in maintenance hemodialysis (MHD) patients is 3 to 5 times higher than that in ordinary people, so it is essential to find the associated risk factors in this population. This project intends to evaluate whether changes in cerebral blood flow during dialysis have an impact on cognitive function in middle-aged and elderly MHD patients and clarify their influence on brain imaging characteristics. MHD patients who started hemodialysis at 3 to 6 months were selected to examine the difference in middle cerebral artery flow rate before and after dialysis by transcranial Doppler ultrasound to reflect the changes in cerebral blood flow. Changes in the cognitive function scale assessment (memory, executive function, and other five cognitive domains) and brain magnetic resonance imaging examinations are planned to collect both at baseline and after a one-year follow-up. Then the investigator used the multiple linear regression method to analyze the effects of the difference in middle cerebral artery flow on the changes in cognitive function and the characteristics in brain imaging. The investigators anticipate that the characteristics of the influence of changes in cerebral blood flow on cognitive impairment in Chinese MHD patients will be elucidated in this study, which may provide crucial clinical evidence for finding preventive and intervention measures for cognitive impairment in this group of population.

Conditions

  • Hemodialysis
  • Cerebral Blood Flow
  • Cognitive Function
  • Magnetic Resonance Imaging

Sponsors & Collaborators

  • Beijing Shijitan Hospital, Capital Medical University

    lead OTHER

Principal Investigators

  • Yang Luo, MD, PhD · Beijing Shijitan Hospital Affiliated to Capital Medical University

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-09-30
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05555836 on ClinicalTrials.gov